Stopping allopurinol allows uric acid levels to climb back toward wherever they were before treatment, and for most people with gout, that means the conditions that triggered painful flares in the first place gradually reassert themselves. The rebound is not always immediate, but the underlying chemistry starts shifting within days of the last dose. How quickly that translates into joint pain, new crystal deposits, or other consequences depends on factors like how long you were on the drug, whether your uric acid was well controlled, and how much crystal burden your body had already accumulated.
What Allopurinol Actually Does and Why the Effect Reverses
Allopurinol works by blocking an enzyme called xanthine oxidase, which is responsible for converting certain breakdown products into uric acid. While you take it daily, less uric acid is produced, and blood levels drop. Over months and years, that lower uric acid environment allows existing crystal deposits in joints and soft tissues to slowly dissolve back into the bloodstream and get excreted. When you stop, the enzyme resumes its normal activity, uric acid production goes back to its previous rate, and the dissolving process halts or reverses.
This reversal matters because uric acid crystal deposits are the root cause of gout attacks. The crystals accumulate silently for years, and when the immune system notices them, the result is the intense inflammation, swelling, and pain of a flare. Allopurinol does not cure the tendency to overproduce or under-excrete uric acid. It manages it. Remove the management, and the problem returns.
How Quickly Flares Come Back
The timeline varies considerably from person to person. Some people experience a flare within weeks of stopping. Others go months or even longer before the next attack, especially if their crystal burden was relatively low when they discontinued. But the general trajectory is clear: without treatment, uric acid rises, crystals begin accumulating again, and the risk of flares climbs.
One of the counterintuitive aspects of gout is that changes in uric acid level in either direction can provoke a flare. Rapidly dropping uric acid when starting treatment is a well-known trigger, which is why doctors often prescribe a prophylactic anti-inflammatory alongside allopurinol for the first several months. The same instability applies in reverse. When uric acid rises after stopping, the shift itself can destabilize crystal deposits and set off inflammation. Research has confirmed that uric acid levels fluctuate significantly during acute flares, with levels temporarily dropping as the kidneys increase excretion during the inflammatory response, then climbing back up afterward.1PubMed Central. Changes of serum uric acid level during acute gout flare and related factors
People who also have metabolic risk factors like insulin resistance appear to face a higher flare frequency when on urate-lowering therapy and presumably after stopping as well. A prospective study found that patients with higher triglyceride-glucose index values had significantly more gout flares after starting urate-lowering treatment, suggesting that metabolic health modulates flare risk beyond uric acid levels alone.2PubMed. Triglyceride-Glucose Index for predicting gout flare risk post-urate-lowering therapy: a prospective cohort study
Crystal Deposits Persist Longer Than You Might Think
A common misconception is that once uric acid levels are under control, the crystals are gone and you can safely stop. The reality is that crystal dissolution is a slow process, and many patients still harbor significant deposits even while on allopurinol. A study using dual-energy computed tomography (a type of imaging that can directly visualize urate crystal deposits) examined 147 gout patients taking allopurinol and found that roughly two-thirds still had detectable urate crystal deposits. Those whose uric acid levels remained above the treatment target and who had palpable tophi showed the highest prevalence, at about 88%. Even patients with uric acid below target and no palpable lumps still had a 47% rate of detectable crystals.3ACR Meeting Abstracts. Presence of Monosodium Urate Crystals By Dual-Energy Computed Tomography in Gout Patients Treated with Allopurinol
The practical implication is striking: if nearly half of well-controlled patients on active treatment still have crystal deposits lurking in their joints, stopping the drug leaves that reservoir intact and ready to grow. The crystals do not simply vanish once you feel better. They take years of sustained low uric acid levels to fully dissolve, and for many patients, complete crystal clearance may require longer treatment durations than they realize. Stopping early essentially resets the clock.
Why People Stop Taking Allopurinol
Despite the consequences, discontinuation is extremely common. Gout has one of the worst medication adherence rates of any chronic condition, and allopurinol specifically suffers because it is a preventive drug taken during periods when the patient feels fine. When there is no active pain, the motivation to take a daily pill drops.
A primary-care study examining reasons people gave for stopping allopurinol found that the most common reasons were side effects, perceiving no benefit from the treatment, and simply being tired of taking tablets.4PubMed Central. Reasons for discontinuing urate-lowering treatment in community-dwelling adults with gout: results of a primary care-based cross-sectional study A separate survey dug deeper into the psychology and found that about a quarter of patients who were not taking their urate-lowering therapy said they wanted to lead a normal life or think of themselves as a healthy person again. Roughly one in five said they were testing whether they still needed the medication.5PubMed. Why Do Patients With Gout Not Take Allopurinol?
That last reason, the “test stop,” is worth examining. Many people with gout try discontinuing to see what happens, partly because gout flares are episodic. You can go months between attacks even without treatment, which makes it easy to conclude the drug was unnecessary. The trouble is that by the time a flare proves you still needed it, uric acid has been climbing and crystals have been growing for weeks or months. It is a high-cost experiment.
The Underdosing Problem That Precedes Quitting
Before many patients quit entirely, there is often a long period where they were never adequately dosed in the first place. Allopurinol is supposed to be titrated upward until uric acid drops below a specific target, but in practice, this titration rarely happens. Data from a large trial showed that the majority of patients, about 65%, stayed at a fixed dose of 300 mg daily, and only about 20% were ever pushed above that dose. Among those kept at 300 mg, only around 35% reached target uric acid levels. Even among those given higher doses, fewer than half got to target.6The Journal of Rheumatology. What Is Allopurinol Failure and What Should We Do About It?
This matters because patients who never reached adequate uric acid control were never getting the full benefit of the drug. Their crystals were dissolving slowly, if at all. If they then stop, they are essentially returning to square one from a position that was not far from square one to begin with. Part of the reason people report “no benefit” from allopurinol is that they were on too low a dose to produce meaningful benefit. True allopurinol failure, where adequately dosed patients still cannot reach target, is far less common than therapeutic inertia, where the dose was simply never increased enough.
When Stopping Might Be Medically Appropriate
There are legitimate medical reasons to stop allopurinol, and the most urgent is a hypersensitivity reaction. Allopurinol hypersensitivity syndrome can range from a mild rash to life-threatening conditions like Stevens-Johnson syndrome and toxic epidermal necrolysis. A large population study in Taiwan documented an overall incidence of allopurinol hypersensitivity of roughly 5 per 1,000 new users, with hospitalization needed in about 2 per 1,000. A small fraction of those cases were fatal.7JAMA Internal Medicine. Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan
The risk is strongly linked to a genetic marker, HLA-B*5801, which is more common in people of Southeast Asian, Korean, and African American descent. Testing for this marker before prescribing allopurinol is now recommended in many guidelines, since identifying carriers can prevent the most dangerous reactions entirely.8PubMed Central. Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population If you develop any kind of skin reaction, fever, or unusual symptoms after starting allopurinol, stopping immediately and contacting your doctor is the right call. In these cases, the risks of continuing clearly outweigh the risks of stopping.
Other reasons a doctor might advise stopping include drug interactions, liver function concerns, or a decision to switch to a different urate-lowering medication like febuxostat. In each of these situations, the stopping is deliberate and managed rather than a unilateral decision to see what happens.
What About Your Kidneys?
One question people often have is whether stopping allopurinol will hurt their kidneys. High uric acid has long been associated with declining kidney function, and there was a period when doctors assumed that lowering uric acid with allopurinol would protect the kidneys. Some earlier evidence supported this idea, with a review of studies suggesting allopurinol appeared to delay kidney disease progression in patients with high uric acid and chronic kidney disease.9PubMed. A review investigating the effect of allopurinol on the progression of kidney disease in hyperuricemic patients with chronic kidney disease
However, a rigorous randomized trial published in the New England Journal of Medicine challenged this. The CKD-FIX trial compared allopurinol to placebo in patients with stage 3 or 4 chronic kidney disease and found no significant difference in the rate of kidney function decline between the two groups. The allopurinol group lost kidney function at essentially the same rate as the placebo group.10PubMed. Effects of Allopurinol on the Progression of Chronic Kidney Disease This does not mean uric acid is irrelevant to kidney health, but it does mean the straightforward assumption that allopurinol protects kidneys has not held up in the strongest trials. If kidney protection was your primary reason for taking allopurinol (as opposed to gout prevention), the evidence that stopping will accelerate kidney decline is weaker than previously believed.
What About Your Heart?
A similar story played out with cardiovascular health. Elevated uric acid tracks closely with heart disease risk, and there were good theoretical reasons to think lowering it might help. The ALL-HEART trial, a large randomized study, tested this directly by giving allopurinol to patients with established heart disease and comparing outcomes to usual care. The results were definitive: allopurinol provided no cardiovascular benefit. Rates of major cardiovascular events were essentially identical, about 11% in both groups, and death rates did not differ.11The Lancet. Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease
This finding reshapes the conversation about stopping. If you were prescribed allopurinol purely for its hypothesized cardiovascular benefit rather than for gout, the evidence now suggests you were not gaining cardiac protection from it. Stopping would not sacrifice a heart benefit that was never there. Of course, if you have gout and heart disease, the primary reason to stay on allopurinol is still gout management.
How to Stop Safely If You and Your Doctor Decide To
If there is a legitimate reason to discontinue, the transition matters. Abruptly stopping can provoke a flare for the same reason that abruptly starting can: rapid changes in uric acid destabilize crystal deposits. Some doctors advise a gradual taper, though formal guidance on the best tapering protocol for discontinuation is limited. More important is having a plan for managing flares during the transition.
The same anti-inflammatory prophylaxis used when starting allopurinol can be applied when stopping. Low-dose colchicine, taken daily for several months, reduces both the frequency and severity of acute flares during periods of uric acid instability.12PubMed. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis International guidelines list low-dose colchicine and low-dose NSAIDs as first-line prophylactic options, with low-dose corticosteroids as an alternative when those are not suitable.13PubMed. Prophylaxis for acute gout flares after initiation of urate-lowering therapy While these recommendations were developed for the start of therapy, the underlying logic applies equally to any period when uric acid levels are shifting.
Having an acute flare plan is also worth discussing with your doctor before you stop. Knowing which anti-inflammatory to take at the first sign of a flare, having it on hand, and understanding when to start it can turn a potential multi-day ordeal into a manageable event.
The “Test Stop” and What It Actually Tells You
For the roughly one in five patients who stop allopurinol to test whether they still need it, the experiment is poorly designed. Gout is episodic by nature. Between attacks, the disease is silent. A person can go six months without a flare and conclude they are cured, only to wake up at 2 a.m. with an excruciating toe. The absence of flares after stopping does not mean the underlying problem resolved. Uric acid may be climbing steadily, crystals may be forming in joints, and the immune system simply has not reacted yet.
A more informative test would be to check uric acid levels a few weeks after stopping. If the level has jumped back above the crystallization threshold (which sits around 6.8 mg/dL under normal body conditions), the biochemistry is heading in the wrong direction regardless of how you feel. The problem with relying on symptoms alone is that by the time symptoms arrive, you have already lost months of crystal dissolution and may have added new deposits that will take additional months of future treatment to clear.
There is one narrow scenario where a test stop has some legitimacy. If you had a single, isolated gout flare years ago, have been on allopurinol for a long period with consistently low uric acid, have no tophi, and have made significant lifestyle changes that independently lower uric acid (like substantial weight loss), your doctor might consider a carefully monitored trial off the drug. This is a medical decision, not a DIY experiment, and it requires follow-up blood work to check where uric acid settles without the medication.
Allopurinol’s Role in Asymptomatic Hyperuricemia
A growing number of allopurinol prescriptions have been written not for gout but for asymptomatic hyperuricemia, meaning elevated uric acid without any joint symptoms. In Taiwan, the proportion of new allopurinol users with asymptomatic hyperuricemia rose from about 37% to nearly 50% over a seven-year period.7JAMA Internal Medicine. Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan This trend is concerning because the evidence for treating asymptomatic hyperuricemia with allopurinol is thin. The drug carries real risks, including hypersensitivity reactions, and the kidney and cardiovascular benefits that were once assumed have largely failed to materialize in randomized trials.
If you are taking allopurinol for high uric acid without ever having had gout, stopping may carry fewer consequences than you expect. Without crystal deposits to worry about, the main risk of stopping is theoretical: that persistently high uric acid might eventually cause gout or contribute to kidney stones. Whether that risk justifies the risks and inconvenience of indefinite medication is a conversation worth having with your doctor, armed with the knowledge that the strongest trials have not shown clear organ-protective benefits from treating the number alone.
What Happens to Tophi
Tophi, the chalky lumps of urate crystals that form under the skin or around joints in advanced gout, are among the most visible consequences of uncontrolled uric acid. They shrink and sometimes disappear entirely with sustained urate-lowering therapy, but the process is glacially slow, often taking a year or more of consistently low uric acid levels. If you stop allopurinol while tophi are still present, they will stop shrinking and can begin growing again as uric acid rises.
Even tophi that appeared to have resolved clinically may still contain microscopic crystal deposits. The imaging data showing that nearly half of patients with no palpable tophi and below-target uric acid still had detectable crystal deposits on advanced scanning illustrates how deceptive surface appearances can be.3ACR Meeting Abstracts. Presence of Monosodium Urate Crystals By Dual-Energy Computed Tomography in Gout Patients Treated with Allopurinol Large tophi can cause joint erosion, compress nerves, and become infected. For patients with tophaceous gout, stopping allopurinol is a particularly risky decision, as the consequences extend beyond pain into potential structural joint damage.
In some cases where tophi are disfiguring or mechanically problematic and medical therapy is not adequately shrinking them, surgical removal has been used. But surgery does not address the underlying uric acid problem, and without continued urate-lowering therapy, new tophi can form at the same or different sites. The surgical option is a complement to, not a replacement for, keeping uric acid down.